Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
2009
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer
2006
Acute Biological Effects of Simulating the Whole-Body Radiation Dose Distribution from a Solar Particle Event Using a Porcine Model
2011 StandoutNobel
Engineering precision nanoparticles for drug delivery
2020 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial
2001
Pancreatic cancer
2004 Standout
The management of respiratory motion in radiation oncology report of AAPM Task Group 76a)
2006 Standout
Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer
2005
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Generalist plus Specialist Palliative Care — Creating a More Sustainable Model
2013 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Foxp2 controls synaptic wiring of corticostriatal circuits and vocal communication by opposing Mef2c
2016 StandoutNobel
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594
2001
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Lung Cancer
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Drug development from marine natural products
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Dose Escalation of Gemcitabine Is Possible With Concurrent Chest Three-Dimensional Rather Than Two-Dimensional Radiotherapy: A Phase I Trial in Patients With Stage III Non–Small-Cell Lung Cancer
2008
Lung cancer: New biological insights and recent therapeutic advances
2011
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
Molecular mechanisms of cisplatin resistance
2011 Standout
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens
2001
Lung cancer: current therapies and new targeted treatments
2016 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Cancer genes and the pathways they control
2004 Standout
Chemotherapy and the war on cancer
2005 Standout
Cellular processing of platinum anticancer drugs
2005 Standout
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
2005
Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer
1999
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
2006
Death Receptor 5 and Bcl-2 Protein Expression as Predictors of Tumor Response to Gemcitabine and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer
2003
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
2004
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients
2006
Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer
2011
Role of gemcitabine in cancer therapy
2005
Postnatal Loss of Mef2c Results in Dissociation of Effects on Synapse Number and Learning and Memory
2015
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
2014
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC
2004
ZD0473 treatment in lung cancer: an overview of the clinical trial results
2002
Phase 2 study of cryptophycin 52 ( LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer
2003
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
2004
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
2007
Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
2002
Platinum drugs in the treatment of non-small-cell lung cancer
2002
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
2004
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma
2006
Overview of the Tolerability of Gefitinib (IRESSA???) Monotherapy
2004
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma
2001
Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer
2001
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer
2004
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Pancreatic cancer
2011 Standout
Mechanisms in the Pathogenesis of Asbestosis and Silicosis
1998 Standout
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
2009
Filopodia formation driven by membrane glycoprotein M6a depends on the interaction of its transmembrane domains
2015
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer
2007
Association Between Palliative Care and Patient and Caregiver Outcomes
2016 Standout
From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.
2006
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
2004
European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer
2010
The Lymphatic System: Integral Roles in Immunity
2016 Standout
Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431
2002
Chemotherapy for advanced gastric cancer
2017 Standout
Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
2001
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
2002
Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors
2007
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
2008 Standout
Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer
2000
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
2002
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
2001
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
2007
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Chrysotile asbestos exposures can produce an alveolitis with limited fibrosing activity in a subset of high fibre retainer sheep
1990
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Programmed co-delivery of platinum nanodrugs and gemcitabine by a clustered nanocarrier for precision chemotherapy for NSCLC tumors
2019
Works of Anne Gregor being referenced
An audit of 3D treatment planning facilities and practice in the UK
1998
Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression
2010
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
2000
The role of histocompatibility (HLA) antigens in asbestosis
1979
A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer.
2003
AlteredGPM6A/M6Dosage Impairs Cognition and Causes Phenotypes Responsive to Cholesterol in Human andDrosophila
2014